Multiplexed COVID-19 antibody quantification from human sera using label-free nanoplasmonic biosensors.
Wihan AdiDhruv BiswasMiriam A ShelefFiliz YesilkoyPublished in: Biomedical optics express (2022)
Serological assays that can reveal immune status against COVID-19 play a critical role in informing individual and public healthcare decisions. Currently, antibody tests are performed in central clinical laboratories, limiting broad access to diverse populations. Here we report a multiplexed and label-free nanoplasmonic biosensor that can be deployed for point-of-care antibody profiling. Our optical imaging-based approach can simultaneously quantify antigen-specific antibody response against SARS-CoV-2 spike and nucleocapsid proteins from 50 µL of human sera. To enhance the dynamic range, we employed multivariate data processing and multi-color imaging and achieved a quantification range of 0.1-100 µg/mL. We measured sera from a COVID-19 acute and convalescent (N = 24) patient cohort and negative controls (N = 5) and showed highly sensitive and specific past-infection diagnosis. Our results were benchmarked against an electrochemiluminescence assay and showed good concordance (R∼0.87). Our integrated nanoplasmonic biosensor has the potential to be used in epidemiological sero-profiling and vaccine studies.
Keyphrases
- label free
- sars cov
- coronavirus disease
- single cell
- respiratory syndrome coronavirus
- healthcare
- high resolution
- endothelial cells
- high throughput
- induced pluripotent stem cells
- liver failure
- case report
- mental health
- sensitive detection
- respiratory failure
- emergency department
- data analysis
- risk assessment
- big data
- machine learning
- artificial intelligence
- intensive care unit
- energy transfer
- photodynamic therapy
- acute respiratory distress syndrome
- mass spectrometry